-
Ebb & Flow LP tracks Janine Guillot stepped down as chief operating investment officer at the California Public Employees' Retirement System (CalPERS), effective May 24. Carol Moody was named interim COIO by CalPERS…
Published on 6/17/2013
-
Living the dream Money Raised in 2013 Last week, the biotech industry raised $532 million, bringing to $12.6 billion the total raised year-to-date. In 2012, a total of $36.2 billion was raised, including $19.9 …
Published on 6/17/2013
-
Ebb & Flow Living the dream PeptiDream Inc. (Tokyo:4587) jumped over 400% in its first week of trading, but due to rules on daily price limits, there's no telling what investors are really willing to pay for the …
Published on 6/17/2013
-
Ebb & Flow Broader spectrum Prism Pharma Co. Ltd. plans to use the $15 million it raised in a series C round last week to expand the Japanese company's focus beyond cancer and beef up its valuation. New investor …
Published on 6/17/2013
-
Level-headed enthusiasm IPO performance Thus far in 2013, 16 biotechs have raised $965 million from IPOs. Ten were completed in the second quarter for $636.6 million. The group is up a median of 26% from their …
Published on 6/17/2013
-
Level-headed enthusiasm IPO queue At least 20 companies have proposed IPOs, including 14 announced since the start of April. Unless noted, the companies are seeking to list on NASDAQ. Most recent filing at top. (A) …
Published on 6/17/2013
-
Ebb & Flow Breaching Myriad's walls Myriad Genetics Inc. (NASDAQ:MYGN) jumped more than 10% in intraday trading Thursday as the company claimed victory on a U.S. Supreme Court ruling allowing cDNA patents. But the …
Published on 6/17/2013
-
Ebb & Flow Funding QB3 The California Institute for Quantitative Biosciences (QB3) and venture affiliate Mission Bay Capital hope to become self-sustaining, but they aren't there yet. Mission Bay aims to raise over…
Published on 6/17/2013
-
Ebb & Flow Regulatory milestones Alimera Sciences Inc. (NASDAQ:ALIM) was up $0.56 (12%) to $5.05 last week after the U.K.'s NICE issued draft guidance recommending Iluvien fluocinolone acetonide intravitreal implant…
Published on 6/17/2013
-
Ebb & Flow Easy come, easy go Theravance Inc. (NASDAQ:THRX) treaded water Friday as investors digested the possibility that the company's proposed sale of royalties to Elan Corp. plc (NYSE:ELN) may get scuttled by …
Published on 6/17/2013
-
Bankers and buysiders agree: As long as quality companies remain on offer and valuations are fair, biotech IPOs will keep thriving as large cap performance and fund inflows mean investors have cash for new stories.
Published on 6/17/2013
-
Figure: Money Raised in 2013 Table: ASCO movers After presenting early Phase I data at ASCO, Clovis Oncology Inc. (NASDAQ:CLVS) got back more …
Published on 6/10/2013
-
Ebb & Flow Money Raised in 2013 Last week, the biotech industry raised $611 million, bringing to $12.1 billion the total raised year-to-date. In 2012, a total of $36.2 billion was raised, including $19.9 billion in …
Published on 6/10/2013
-
Ebb & Flow ASCO movers At least eight biotechs gained or lost more than 10% last week after presenting at the American Society of Clinical Oncology meeting in Chicago. Clovis Oncology Inc. (NASDAQ:CLVS) topped the …
Published on 6/10/2013
-
Ebb & Flow Tip-toeing on the bubble PeptiDream Inc. could be facing choppy waters as it makes its public debut this Tuesday in Japan. Last week, the macrocycle company raised ¥5.3 billion ($52.4 million) through …
Published on 6/10/2013
-
Ebb & Flow Regulatory milestones AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) gained $0.24 to $19.79 on Friday after partner Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) submitted a Type II variation application to EMA to…
Published on 6/10/2013
-
Ebb & Flow Regenerative reservoir Sosei Group Corp. (Tokyo:4565) is launching a ¥2 billion ($19.9 million) seed fund to invest in Japanese regenerative medicine companies that will give the portfolio companies time …
Published on 6/10/2013
-
Ebb & Flow Floating across the pond A booming U.S. IPO market has some private European biotechs thinking about whether to make the leap over the pond. The decisions of two companies show that a U.S. listing may be …
Published on 6/10/2013
-
Ebb & Flow Analyst tracks Catherine Arnold joined Wellington Management as a global industry analyst. She was a managing director and senior analyst for U.S. pharmaceuticals at Credit Suisse. Andrew Fein joined H.C…
Published on 6/3/2013
-
Okairos is OK Money Raised in 2013 Last week, the biotech industry raised $197 million, bringing to $11.5 billion the total raised year-to-date. In 2012, a total of $36.2 billion was raised, including $19.9 billion …
Published on 6/3/2013
-
Lacking an abundance of worthwhile venture deals, Novo A/S is putting its cash flow to work by expanding its growth equity investments in mature life science companies like Xellia.
Published on 6/3/2013
-
Ebb & Flow Part-way financing Ophthotech Corp. did two deals last week that could bring in $175 million, but the biotech expects it still will need additional capital to complete a Phase III trial of Fovista for wet…
Published on 6/3/2013
-
Ebb & Flow Regulatory milestones Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) gained $12.74 (21%) to $72.83 last week after at least two analysts raised their price targets on the stock and EMA's CHMP backed approval…
Published on 6/3/2013
-
Ebb & Flow Okairos is OK Figure: Money Raised in 2013 Okairos AG rewarded investors who helped spin the T cell vaccine developer out of Merck & Co Inc. (NYSE:MRK) in 2007. The €250 million ($323 million) that …
Published on 6/3/2013
-
Ebb & Flow Money on the table Sofinnova Partners and NEA turned a tidy profit from last week's sale of Omthera Pharmaceuticals Inc. (NASDAQ:OMTH) to AstraZeneca plc (LSE:AZN; NYSE:AZN), though it might have been …
Published on 6/3/2013